A.J. HERRINGTON MAY 14, 2020
The U.S. Food and Drug Administration has issued warning letters to two companies for making unsubstantiated claims that their CBD products can be used as an alternative to opioids or as a treatment for opioid addiction. The letters were sent to BIOTA Biosciences, LLC in the state of Washington and Homero Corp DBA Natures CBD Oil Distribution of New Hampshire, the FDA announced on April 23.
“…“It’s obvious that the FDA will not become a relaxed agency when dealing with the CBD market and ludicrous claims being made,” he said. “This trend of FDA enforcement will likely continue, especially in times like the period we are experiencing around the world at this very moment…”